Verseon Corporation Lower bleeding risk of Verseon anticoagulants
December 06 2016 - 1:01AM
RNS Non-Regulatory
TIDMVSN
Verseon Corporation
06 December 2016
Press release December 6, 2016
Verseon Corporation
("Verseon" or the "Company")
ASH 2016: Explaining the lower bleeding risk of Verseon's
anticoagulants
FREMONT, Calif.-Verseon presented preclinical results at the
American Society of Hematology (ASH) Annual Meeting in San Diego
yesterday that could explain the favorable bleeding profile of its
novel class of oral direct thrombin inhibitors. The data indicate
that Verseon's drug candidates do not disrupt platelet function
while preventing thrombosis in preclinical efficacy models.
During the clotting process, thrombin cleaves fibrinogen as a
basis for clot formation and also activates platelets, which play
an important role in wound healing, hemostasis, and healthy tissue
growth. By either directly or indirectly inhibiting thrombin, novel
oral anticoagulants (NOACs) also reduce platelet activation, which
may, in turn, increase a patient's bleeding risk.
Preclinical data presented at the conference show that while
Verseon's direct thrombin inhibitors (VE--DTIs) prevent thrombosis
in in vivo efficacy models such as the arteriovenous shunt and
thrombin-induced thromboembolism models, the VE-DTIs leave platelet
function unaffected. This finding has been confirmed by Verseon via
tests that assess in vivo platelet activation in these models using
flow cytometry with platelet-specific antibodies. These in vivo
results support in vitro data that show that the VE-DTIs are highly
selective thrombin inhibitors that effectively block fibrinogen
cleavage, but are up to 900--fold less potent in the in vitro
inhibition of platelet activation than currently available
NOACs.
"This unique feature of our novel class of thrombin inhibitors
provides a biological explanation for their low bleeding
liability," said Dr. Mohan Sivaraja, Verseon's Associate Director
of Discovery Biology, who presented these findings at ASH. "These
encouraging results further establish the distinctive pharmacology
of our compounds."
About Verseon's Anticoagulant Program
Verseon's potent, highly selective, oral direct thrombin
inhibitors act through reversible covalent inhibition, a unique
mode of action. Preclinical studies show that Verseon's inhibitors
act as effective anticoagulants in multiple efficacy studies, but
do not disrupt platelet function. This unique feature could explain
their observed low bleeding risk. One of Verseon's lead candidates
furthermore shows very low renal clearance, a highly desirable
property for patients with impaired renal function.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that employs its
proprietary, computational drug discovery platform to develop novel
therapeutics that are unlikely to be found using conventional
methods. The Company is applying its platform to a growing drug
pipeline and currently has three active drug programs in the areas
of anticoagulation, diabetic macular edema, and oncology.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Arthur Shmurun / Amy Thai 9000
Cenkos Securities (NOMAD and +44 (0) 20
Joint Broker) 7397 8900
Cantor Fitzgerald Europe (Joint +44 (0) 20
Broker) 7894 7000
Mirabaud Securities LLP (Joint +44 (0) 20
Broker) 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd +44 (0) 20
(PR Advisers) 7466 5000
For trade and pharma media enquiries, please contact
+44 (0) 1737
Vane Percy & Roberts 821 890
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALIFFRFILRIIR
(END) Dow Jones Newswires
December 06, 2016 02:01 ET (07:01 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2023 to Apr 2024